GLP1R and type 2 diabetes mellitus: Thus far, only SGLT2is, glucagon-like peptide-1 (GLP1) receptor agonists, and metformin lead to BW loss, largely accounted for by body fat reduction [39], whereas other oral hypoglycemic agents and insulin have long been associated with BW gain in patients with T2DM [40, 41].